Pharmaceuticals News and Research

RSS

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows.

14 Mar 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

14 Mar 2011

AbCheck licenses CELEXION yeast display technology for an industry first

AbCheck s.r.o., the multi antibody discovery platforms company, announced today the company has licensed a proven antibody yeast display technology from CELEXION LLC (Cambridge, MA, USA). The addition of this platform to AbCheck's current phage display platform places the company as the World's only antibody discovery specialist leveraging the advantage of working with both phage and yeast display technologies.

14 Mar 2011

SOM Biotech closes first financing round and files patent application

SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.

14 Mar 2011

Spaulding Clinical announces 510k approval for ECG device

Leading-edge Clinical Pharmacology and Cardiac Core Lab provider, Spaulding Clinical Research, proudly announces the 510k approval of their proprietary ECG device platform: Spaulding IQ.

14 Mar 2011

CTI, Chroma enter agreement to co-develop and license tosedostat

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

14 Mar 2011

External panel issues draft report saying WHO response to H1N1 lacked cohesion, clarity

An independent panel of experts commissioned by the WHO to probe its response to the H1N1 pandemic on Thursday released a draft report stating that while the organization performed well in many ways, it made "crucial mistakes" and "warned tens of millions could die if there is a severe flu outbreak in the future," the Associated Press reports.

14 Mar 2011

Nanotechnology might provide greater efficacy of medicines for brain disease

Technology has been developed within Top Institute Pharma that helps medicines be absorbed quicker into the blood and thus be more effective. Researcher Hans de Waard, who is associated with the University of Groningen, will obtain his doctorate on this subject on March 11. De Waard: "Many current medicines are not easily dissolved in the digestive tract, which means that they barely reach the bloodstream.

14 Mar 2011

US District Court rules in favor of Watson in FENTORA patent litigation

On March 11, 2011, the United States District Court for the District of Delaware issued a decision as to a portion of the patent litigation brought by Cephalon Inc., and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., pertaining to Cephalon's FENTORA® fentanyl buccal tablet product.

14 Mar 2011

Swine flu pandemic declaration by WHO being investigated by experts

Experts who have been investigating the World Health Organization’s management of the response to the H1N1 pandemic have announced that they found no evidence that the drug industry influenced the agency’s decision making over how to handle the virus. In their draft report that panel of independent experts did acknowledge that the WHO failed to understand and respond to conflicts of interest among experts on its advisory Emergency Committee, which had previously acknowledged their pharmaceutical industry ties.

14 Mar 2011

Provepharm receives favorable EMA Review of its methylthioninium chloride Proveblue

Provepharm, a start-up specialized in the development of pharmaceutical applications, announces today that, following a one-year centralized review procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CMPH) issued a favorable assessment of its methylthioninium chloride Proveblue on 17 February.

12 Mar 2011

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.

11 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Bill Gates and Schrödinger co-founder invest in Nimbus to advance large B-cell lymphoma programs

Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

11 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.

11 Mar 2011